RAPT
RAPT Therapeutics Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.
Market Cap: 314 Million
Primary Exchange: NASDAQ
Website: https://www.rapt.com/
Shares Outstanding: 34.4 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.5899954328520065
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 480 trading days
From: 2020-01-27 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|